Replies to post #232366 on Biotech Values

[Whalatane]

Xavier. Strongly suggest she add Vascepa and drop Omega 3 supplements .
There is no clinical evidence in a US population that regular EPA/DHA fish oils do anything to reduce risk of heart attack or stroke .
There is Outcome trial data to show that Vascepa with Statins is very effective at reducing CV risk .
The data I mentioned this am has been picked up by Globe news wire ...AMRN spiked when the following was released

VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study
GlobeNewswire

Briefing.com


Quote:

Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular

Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001).
Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).

The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors.

Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively.

In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005

my emphasis
Kiwi